0 Engagements
BENGALURU: India reported a smaller rise in daily coronavirus infections for a third straight day yesterday, as the government said it was working to boost vaccine supplies to avert deaths beyond the pandemic toll of more than 270,000.
The number of deaths in the past 24 hours rose over 4,000 for the fourth time in a week, with yesterday s 311,170 new infections representing the lowest single-day rise in more than three weeks.
Federal health officials warned against interpreting a plateauing in the rise as a sign for complacency, however, and urged states to add intensive care units and strengthen their medical workforce.
Even though India is the world s largest vaccine-producing nation, it has fully vaccinated only 2.9 per cent of its population of 1.35 billion, or just over 40.4 million people, Health Ministry data shows.
India reported a smaller rise in daily COVID-19 cases for the third straight day on Sunday, but the number of deaths in 24 hours was higher than 4,000, taking the country's death toll to 270,000.
DRDO s anti-Covid drug 2-DG launched
By IANS |
0 Views
DRDO s anti-Covid drug 2-DG launched
. Image Source: Twitter/PIB India
New Delhi, May 17 : The first batch of DRDO-developed anti-Covid drug 2-DG (2-deoxy-D-glucose) was launched on Monday to treat patients suffering from the deadly disease. The medicine comes in powder form and can be taken with water.
Defence Minister Rajnath Singh and Health Minister Harsh Vardhan released the first batch of the 2-DG, an anti-Covid-19 therapeutic application of the drug developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO) in collaboration with Dr Reddy s Laboratories (DRL).
India's daily Covid cases dropped below the 3 lakh-mark for the first time since April 21 with 2.81 lakh fresh infections reported in the last 24 hours. 4,106 Covid patients have died since yesterday.
Covaxin effective against India,UK COVID strains: Bharat Biotech
The study found a modest reduction in neutralisation by a factor of 1.95 against B.1.617 variant compared to vaccine variant D614G, Bharat Biotech noted.
By PTI| Posted by Sakina Fatima | Published: 17th May 2021 1:35 pm IST
New Delhi: Bharat Biotech on Sunday said its COVID-19 vaccine ‘Covaxin’ has been found to be effective against COVID-19 virus strains found in India and the UK.
Citing a study published in peer-reviewed medical journal Clinical Infectious Diseases, the Hyderabad-based vaccine major noted that vaccination with Covaxin produced neutralising titres against all key emerging variants tested, including B.1.617 and B.1.1.7, first identified in India and the UK, respectively.